Cannabis Banking Legislation and the Business Impact of Rescheduling

The cannabis industry is currently standing on the precipice of the most significant regulatory shift in its history. With the United States Department of Justice (DOJ) officially moving to reclassify marijuana from a Schedule I to a Schedule III controlled substance in 2024, the financial landscape for cannabis businesses is about to change drastically. This move addresses the core struggles of the industry: crushing tax burdens and limited access to banking services.

The Shift from Schedule I to Schedule III

To understand the business impact, you must first understand the classification. Since 1970, cannabis has been a Schedule I drug under the Controlled Substances Act. This placed it in the same category as heroin and LSD, defined as having “no currently accepted medical use and a high potential for abuse.”

The proposed move to Schedule III places cannabis alongside drugs like Tylenol with codeine and testosterone. This reclassification acknowledges medical utility and lower abuse potential. While this does not federally legalize recreational use, it fundamentally alters how businesses operating in state-legal markets interact with the federal tax code and financial institutions.

The End of Section 280E: A Tax Revolution

The most immediate and concrete financial benefit of rescheduling is the elimination of Internal Revenue Code Section 280E. This tax provision has historically been the single largest hurdle to profitability for cannabis operators.

Section 280E forbids businesses trafficking in Schedule I or II substances from deducting standard business expenses. While a normal coffee shop can deduct rent, payroll, marketing, and utilities from their gross income before paying taxes, a cannabis dispensary cannot. They are taxed on their gross profit rather than their net income.

The Numbers Behind 280E

Currently, effective tax rates for cannabis companies often exceed 70%. In some cases, businesses with low profit margins actually pay more in taxes than they make in profit.

If rescheduling is finalized, Section 280E will no longer apply to state-legal cannabis businesses. The impact will be immediate:

  • Cash Flow: Major Multi-State Operators (MSOs) like Curaleaf, Trulieve, and Green Thumb Industries generally pay over $100 million annually in taxes related to 280E. Removing this burden frees up massive amounts of capital for reinvestment.
  • profitability: Many operators that are currently reporting net losses on paper would instantly flip to profitability once standard corporate tax rates (21%) are applied to their actual net income rather than gross receipts.

Banking Access and the SAFER Banking Act

While rescheduling solves the tax issue, the banking issue is more complex. For years, the industry has lobbied for the SAFER Banking Act (Secure and Fair Enforcement Regulation Banking Act). This legislation is designed to provide safe harbor to banks and credit unions that work with state-legal cannabis clients.

Currently, major financial institutions like JPMorgan Chase or Bank of America largely refuse to service the industry due to strict anti-money laundering (AML) laws. This forces a multi-billion dollar industry to operate largely in cash, increasing risks of theft and complicating payroll.

How Rescheduling Affects Banking

Rescheduling marijuana to Schedule III does not automatically grant banking access in the same way the SAFER Banking Act would. However, it significantly lowers the risk profile for banks.

  • Reputational Risk: Banks often cite “reputational risk” and high compliance costs for avoiding cannabis. Schedule III status removes the stigma of dealing with a “drug with no medical use.”
  • Credit Cards: Currently, major networks like Visa and Mastercard do not allow cannabis transactions on their rails. A move to Schedule III could encourage these payment processors to revisit their internal policies, potentially allowing consumers to use credit cards at dispensaries rather than relying on “cashless ATM” workarounds.

Investment and Stock Market Uplisting

The “Holy Grail” for cannabis business growth is access to major U.S. stock exchanges. Currently, American cannabis companies cannot list on the New York Stock Exchange (NYSE) or Nasdaq because they handle a Schedule I substance. Instead, they trade on the Canadian Securities Exchange (CSE) or Over-the-Counter (OTC) markets in the U.S.

This relegation to smaller exchanges limits access to institutional capital. Pension funds, mutual funds, and large asset managers often have charters preventing them from investing in companies that violate federal law or trade on OTC markets.

The Path to Uplisting

If cannabis becomes a Schedule III drug, the argument for blocking uplisting weakens. While the exchanges are private entities with their own rules, the federal illegality barrier is lowered.

  • Liquidity: If companies like Verano Holdings or Cresco Labs can list on the Nasdaq, it opens the door to billions in institutional investment.
  • Cost of Capital: Currently, cannabis companies pay high interest rates (often 12% to 15% or higher) for debt financing because lenders view them as high-risk. With better cash flow from 280E relief and better standing with banks, the cost of borrowing money will drop, accelerating expansion.

Operational Changes and Safety

Beyond the balance sheet, rescheduling impacts daily operations. The heavy reliance on cash makes dispensaries targets for robbery.

  • Security Costs: Businesses currently spend heavily on armored car transport and secure cash storage. Banking access reduces the physical volume of cash moving through the supply chain.
  • Payroll: Many smaller cannabis employees are still paid in cash or via complex third-party payroll processors that charge high fees. Normalized banking allows for standard direct deposit systems.

Frequently Asked Questions

Does rescheduling to Schedule III legalize marijuana federally? No. It remains a controlled substance. However, it moves it to a regulatory category that acknowledges medical use. Recreational legalization would require an act of Congress to remove it from the Controlled Substances Act entirely (descheduling).

Will dispensaries still need to pay Section 280E taxes for past years? Generally, yes. The IRS typically does not apply tax code changes retroactively for this type of rescheduling. Companies will likely still owe back taxes accumulated under the Schedule I regime, though this may be litigated in tax courts.

When will the rescheduling take effect? The process was initiated by the Attorney General in May 2024. Following the public comment period and review by an Administrative Law Judge, the final rule could be implemented in late 2024 or early 2025.

Does this mean I can use a credit card at a dispensary? It is likely, but not immediate. Visa and Mastercard are private companies. They will need to update their internal merchant policies after the federal ruling is finalized. However, Schedule III makes this outcome much more probable than it was under Schedule I.